Jul 21 2010
Molecular dermatology research and development innovator DermaGenoma, Inc. today announced that the PsoriasisDX Genetic Test for Psoriatic Arthritis (PsA) is now available as a CE Marked product under the European In Vitro Diagnostic Directive.
“It helps doctors determine the proper treatments for patients.”
CE Marking is required for certain product groups to indicate conformity with the essential requirements set out in European Directives. The PsoriasisDX Genetic Test for Psoriatic Arthritis complies with the essential requirements of the European IVD Directive.
The PsoriasisDX Genetic Test helps identify those at high risk for developing Psoriatic Arthritis before they experience arthritic symptoms, providing the opportunity to lessen joint damage through early medical intervention.
"We are excited to extend this revolutionary genetics testing breakthrough to dermatologists in Europe," says Andy Goren, CEO of DermaGenoma, Inc. "It helps doctors determine the proper treatments for patients."
SOURCE DermaGenoma, Inc.
Some genetic mutations may offer protection against developmental disorders